Details for New Drug Application (NDA): 090033
✉ Email this page to a colleague
NDA 090033 describes RIFABUTIN, which is a drug marketed by Lupin Ltd and Novitium Pharma and is included in two NDAs. It is available from two suppliers. Additional details are available on the RIFABUTIN profile page.
The generic ingredient in RIFABUTIN is rifabutin. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the rifabutin profile page.
The generic ingredient in RIFABUTIN is rifabutin. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the rifabutin profile page.
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 150MG | ||||
| Approval Date: | Feb 24, 2014 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
